Pharmacokinetics/Pharmacodynamics
needing replacement—evidence and implications? A
systematic review. Surgery. 2006;139(3):419-432. https://
doi.org/10.1016/j.surg.2005.07.035
Brown CS, Liu J, Riker RR, et al. Evaluation of free
valproate concentration in critically ill patients. Crit
Care Explor. 2022;4(9):e0746. https://doi.org/10.1097/
cce.0000000000000746
Brown G, Dodek P. An evaluation of empiric vs. nomo-
gram-based dosing of heparin in an intensive care
org/10.1097/00003246-199709000-00021
Case J, Khan S, Khalid R, Khan A. Epidemiology
of acute kidney injury in the intensive care unit.
org/10.1155/2013/479730
Chew ML, Plotka A, Alvey CW, et al. Effect of the
gastrointestinal prokinetic agent erythromycin on the
pharmacokinetics of pregabalin controlled-release in
healthy individuals: a phase I, randomized crossover
trial. Clin Drug Investig. 2015;35(5):299-305. https://doi.
org/10.1007/s40261-015-0281-y
Craig
WA.
Pharmacokinetic/pharmacodynamic
parameters: rationale for antibacterial dosing of mice
and men. Clin Infect Dis. 1998;26(1):1-12. https://doi.
org/10.1086/516284
Cummins CL, Jacobsen W, Benet LZ. Unmasking the
dynamic interplay between intestinal P-glycoprotein and
CYP3A4. J Pharmacol Exp Ther. 2002;300(3):1036-
1045. https://doi.org/10.1124/jpet.300.3.1036
Dahn MS, Lange P, Lobdell K, Hans B, Jacobs LA,
Mitchell RA. Splanchnic and total body oxygen con-
sumption differences in septic and injured patients.
Surgery.
1987;101(1):69-80.
https://doi.org/10.1001/
archsurg.1990.01410160027004
Dailly E, Kergueris MF, Pannier M, Jolliet P, Bourin
M. Population pharmacokinetics of imipenem in burn
patients. Fundam Clin Pharmacol. 2003;17(6):645-650.
https://doi.org/10.1046/j.1472-8206.2003.00190.x
Dasta JF, Armstrong DK. Variability in aminogly-
coside pharmacokinetics in critically ill surgical
org/10.1097/00003246-198804000-00004
De
Paepe
P,
Belpaire
FM,
Buylaert
WA.
Pharmacokinetic and pharmacodynamic considerations
when treating patients with sepsis and septic shock.
Clin Pharmacokinet. 2002;41(14):1135-1151. https://doi.
org/10.2165/00003088-200241140-00002
Desjars P, Pinaud M, Bugnon D, Tasseau F.
Norepinephrine therapy has no deleterious renal effects in
https://doi.org/10.1097/00003246-198905000-00010
Dickerson RN, Hamilton LA, Connor KA, et al.
Increased hypoglycemia associated with renal failure
during continuous intravenous insulin infusion and
specialized nutritional support. Nutrition. 2011;27(7-
8):766-772. https://doi.org/10.1016/j.nut.2010.08.009
Dickerson RN, Lynch AM, Maish GO 3rd, Croce MA,
Minard G, Brown RO. Improved safety with intravenous
insulin therapy for critically ill patients with renal failure.
Nutrition. 2014;30(5):557-562. https://doi.org/10.1016/j.
nut.2013.10.010
Dickerson RN, Maish GO 3rd, Minard G, Brown RO.
Clinical relevancy of the levothyroxine-continuous enteral
nutrition interaction. Nutr Clin Pract. 2010;25(6):646-
652. https://doi.org/10.1177/0884533610385701
Di Giantomasso D, May CN, Bellomo R. Norepinephrine
2002;28(12):1804-1809.
https://doi.org/10.1007/
s00134-002-1444-x
Di Giantomasso D, May CN, Bellomo R. Norepinephrine
and vital organ blood flow during experimental hyperdy-
https://doi.org/10.1007/s00134-003-1736-9
Di Giantomasso D, Morimatsu H, May CN, Bellomo
R. Intrarenal blood flow distribution in hyperdynamic
2003;31(10):2509-2513.
https://doi.org/10.1097/01.
ccm.0000084842.66153.5a
Droege CA, Ernst NE, Foertsch MJ, et al. Assessment of
detectable serum tobramycin concentrations in patients
receiving inhaled tobramycin for ventilator-associated
pneumonia. Respir Care. 2022;67(1):16-23. https://doi.
org/10.4187/respcare.09412
Droege ME, Rhoades AG, Droege CA, et al. Clinical
experience, characteristics, and performance of an acet-
aminophen absorption test in critically ill patients. Am
J Ther. 2023;30(2):e95-e102. https://doi.org/10.1097/
mjt.0000000000001436
Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter
randomized trial of continuous versus intermittent